These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19605509)

  • 1. Phase I study of apoptosis gene modulation with oblimersen within preoperative chemotherapy in patients with primary breast cancer.
    Rom J; von Minckwitz G; Marmé F; Ataseven B; Kozian D; Sievert M; Schlehe B; Schuetz F; Scharf A; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2009 Nov; 20(11):1829-35. PubMed ID: 19605509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
    Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
    Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors.
    Marshall J; Chen H; Yang D; Figueira M; Bouker KB; Ling Y; Lippman M; Frankel SR; Hayes DF
    Ann Oncol; 2004 Aug; 15(8):1274-83. PubMed ID: 15277270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Chi K; Kuhn J; Gleave M; Patnaik A; Takimoto C; Schwartz G; Thompson I; Berg K; D'Aloisio S; Murray N; Frankel SR; Izbicka E; Rowinsky E
    Clin Cancer Res; 2005 May; 11(10):3854-61. PubMed ID: 15897586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer.
    Moulder SL; Symmans WF; Booser DJ; Madden TL; Lipsanen C; Yuan L; Brewster AM; Cristofanilli M; Hunt KK; Buchholz TA; Zwiebel J; Valero V; Hortobagyi GN; Esteva FJ
    Clin Cancer Res; 2008 Dec; 14(23):7909-16. PubMed ID: 19047121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium.
    Margolin K; Synold TW; Lara P; Frankel P; Lacey SF; Quinn DI; Baratta T; Dutcher JP; Xi B; Diamond DJ; Gandara DR
    J Cancer Res Clin Oncol; 2007 Oct; 133(10):705-11. PubMed ID: 17508219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
    Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
    Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
    Sternberg CN; Dumez H; Van Poppel H; Skoneczna I; Sella A; Daugaard G; Gil T; Graham J; Carpentier P; Calabro F; Collette L; Lacombe D;
    Ann Oncol; 2009 Jul; 20(7):1264-9. PubMed ID: 19297314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2 antisense therapy in multiple myeloma.
    Chanan-Khan AA
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):21-4. PubMed ID: 15651173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
    Chi KN
    World J Urol; 2005 Feb; 23(1):33-7. PubMed ID: 15723221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    O'Connor OA; Smith EA; Toner LE; Teruya-Feldstein J; Frankel S; Rolfe M; Wei X; Liu S; Marcucci G; Chan KK; Chanan-Khan A
    Clin Cancer Res; 2006 May; 12(9):2902-11. PubMed ID: 16675587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.